Find an expert
Our panel of editors are available for interview
Theodora Bloom
Executive Editor of the BMJ
Theodora Bloom is executive editor of The BMJ. At the BMJ, Theo’s responsibilities include publishing, business, platform and operations as well as ethical and policy matters. She is a Co-Founder of the medRxiv preprint server, a collaboration between BMJ, Cold Spring Harbor Laboratory and Yale University, and jointly coordinates open access and open research initiatives at BMJ.
Professor Yu-Chuan Jack Li
Editor-in-Chief of BMJ Health & Care Informatics
Professor Yu-Chuan Jack Li is a researcher of artificial intelligence in medicine and medical informatics, and a practising dermatologist. He is currently Dean and distinguished professor at the College of Medical Science and Technology, Taipei Medical University and the Chief of Dermatology at the Centre for Cosmetic and Laser, Paipei Municipal Wanfang Hospital. Professor Li has also served as President of the Asia-Pacific Association for Medical Informatics (APAMI), and President-elect of International Medical Informatics Association (IMIA).
Dr Jinghong Chen
Deputy Editor of General Psychiatry
Dr Jinghong Chen is the joint deputy editor of General Psychiatry. She is currently the principal investigator at Shanghai Key Laboratory of Psychotic Disorders and professor at Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine.
Dr James Cave
Editor-in-Chief of the Drugs and Therapeutics Bulletin
Dr James Cave has been a GP for over 25 years. He currently works for Red Whale, providing courses for GP’s that take the latest research and demonstrate how it might be used in practice. James was awarded an OBE for services to medicine in 2009.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.
